Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials

Figure 4

Incidences of grade 3 and grade 4 hematologic adverse events versus age group. Leucopenia: age <60 years, n = 1,730; age between 60 and 64 years, n = 406; age >64 years, n = 272 (P < 0.001). Neutropenia: age <60 years, n = 1,152; age between 60 and 64 years, n = 326; age >64 years, n = 225 (P < 0.001). Febrile neutropenia: age <60 years, n = 181; age between 60 and 64 years, n = 43; age >64 years, n = 29 (P = 0.430). Anemia: age <60 years, n = 97; age between 60 and 64 years, n = 16; age >64 years, n = 14 (P = 0.674). Thrombopenia: age <60 years, n = 70; age between 60 and 64 years, n = 14; age >64 years, n = 21 (P = 0.002).

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us